Enveric Biosciences, Inc. (ENVB) vs Mangoceuticals, Inc. (MGRX)
A side-by-side comparison of Enveric Biosciences, Inc. and Mangoceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENVB
Enveric Biosciences, Inc.
$1.47HealthcareDelayed quote: Oct 6, 2026, 11:44 AM EDT
MGRX
Mangoceuticals, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — ENVB vs MGRX
growth of $100 · dividends reinvested · last 3yENVB -98.2% (-73.9%/yr)MGRX -99.3% (-80.9%/yr)ENVB compounded faster over this window
ENVB MGRX
ENVB vs MGRX: by the numbers
- •MGRX is the larger company ($7M vs $7M market cap).
- •Both run net losses; ENVB's is the smaller (0.00% vs -4791.48% net margin).
Metrics side by side
Valuation
| Metric | ENVB | MGRX |
|---|---|---|
| P/S ratio | N/A | 22.73 |
| P/B ratio | 0.81 | 0.57 |
Profitability
| Metric | ENVB | MGRX |
|---|---|---|
| Gross margin | 0.00% | 54.43% |
| Operating margin | 0.00% | -4200.46% |
| Net margin | 0.00% | -4791.48% |
| ROE | -108.00% | -120.58% |
| ROIC | -107.99% | -102.91% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.